Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;13(4):353-7.
doi: 10.7861/clinmedicine.13-4-353.

Evidence underlying the clinical management of diabetic macular oedema

Michael Andrew Williams  1 , Usha Chakravarthy
Affiliations
Review

Evidence underlying the clinical management of diabetic macular oedema

Michael Andrew Williams et al. Clin Med (Lond). 2013 Aug.

Abstract

Diabetic retinopathy (DR) is the leading cause of visual loss in the developed world in those of working age, and its prevalence is predicted to double by 2025. The management of diabetic retinopathy has traditionally relied on screening, on laser treatment delivered by ophthalmologists, and on optimising blood glucose and blood pressure. Recent evidence suggests that the role of systemic factors is more complex than originally thought, and that drugs such as ACE inhibitors, fibrates and glitazones may all influence the course of diabetic macular oedema. Antagonism of vascular endothelial growth factor offers a new therapeutic avenue that may transform the management of diabetic macular oedema. Several other therapeutic options are under investigation and development, including aminoguanidine, sorbinol, ruboxistaurin and autologous stem cell transfusion.

Keywords: Retinopathy; diabetes; macular.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Bilateral diabetic macular exudates. The view of the left fundus is blurred due to cataract.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Al-latayfeh MM, Sun JK, Aiello LP. Ocular coherence tomography and diabetic eye disease. Semin Opthalmol 2010;25:192-7.10.3109/08820538.2010.518107 - DOI - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64.10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Romero-Aroca P, Fernandez-Alart J, Baget-Bernaldiz M, et al. Diabetic retinopathy epidemiology in type II diabetic patients. Effect of the changes in the diagnostic criteria and stricter control of the diabetes between 1993 and 2005 on the incidence of diabetic retinopathy. Arch Soc Esp Ofthalmol 2007;82:209-18. - PubMed
    1. Scholl S, Augustin A, Loewenstein A, et al. General pathophysiology of macular edema. Eur J Opthalmol 2010;21:10-19.10.5301/EJO.2010.6050 - DOI - PubMed
    1. Wu M, Chen Y, Wilson K, et al. Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008;49:2679-85.10.1167/iovs.07-1440 - DOI - PubMed